Whalen Wealth Management Inc. Purchases Shares of 2,695 Lantheus Holdings, Inc. (NASDAQ:LNTH)

Whalen Wealth Management Inc. acquired a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 2,695 shares of the medical equipment provider’s stock, valued at approximately $241,000.

A number of other hedge funds have also recently made changes to their positions in LNTH. Envestnet Asset Management Inc. boosted its position in shares of Lantheus by 0.3% during the second quarter. Envestnet Asset Management Inc. now owns 111,498 shares of the medical equipment provider’s stock worth $8,952,000 after buying an additional 356 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Lantheus by 1.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,239,502 shares of the medical equipment provider’s stock valued at $99,525,000 after acquiring an additional 19,071 shares during the period. Mercer Global Advisors Inc. ADV acquired a new position in Lantheus in the 2nd quarter valued at about $209,000. Vanguard Personalized Indexing Management LLC increased its stake in Lantheus by 20.6% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 7,025 shares of the medical equipment provider’s stock worth $564,000 after purchasing an additional 1,202 shares during the period. Finally, XTX Topco Ltd acquired a new stake in shares of Lantheus during the second quarter worth about $313,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Price Performance

NASDAQ:LNTH opened at $95.39 on Thursday. Lantheus Holdings, Inc. has a 12 month low of $50.20 and a 12 month high of $126.89. The firm has a market capitalization of $6.63 billion, a PE ratio of 15.87 and a beta of 0.46. The business’s fifty day moving average price is $90.36 and its 200 day moving average price is $100.29.

Insider Activity

In related news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the sale, the director now directly owns 33,207 shares in the company, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on LNTH shares. The Goldman Sachs Group initiated coverage on shares of Lantheus in a report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective for the company. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Truist Financial reiterated a “buy” rating and issued a $120.00 price objective (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. Finally, JMP Securities reissued a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, Lantheus presently has a consensus rating of “Moderate Buy” and a consensus price target of $131.86.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.